Date published: 2026-9-8

1-800-457-3801

SCBT Portrait Logo
Seach Input

YME1L1 CRISPR/Cas9 KO Plasmid (m): sc-424248

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • YME1L1 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the YME1L1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    YME1L1 CRISPR/Cas9 KO Plasmid (m)

    sc-424248
    20 µg
    $397.00

    Overview

    Yme1l1 encodes YME1L1, an ATP-dependent i-AAA metalloprotease embedded in the inner mitochondrial membrane that performs quality control by degrading misfolded or damaged proteins and processing key regulators of mitochondrial dynamics. By controlling turnover of substrates involved in OPA1-dependent inner membrane fusion, respiratory chain integrity, and proteostasis, YME1L1 helps maintain cristae architecture and mitochondrial bioenergetic function. Loss or dysregulation of YME1L1 perturbs mitophagy, elevates mitochondrial stress signaling, and can promote fragmentation, altered oxidative phosphorylation, and apoptosis susceptibility. These processes are widely relevant to models of neurodegeneration, cardiometabolic dysfunction, and other disorders linked to impaired mitochondrial homeostasis.

    YME1L1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Yme1l1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Yme1l1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Yme1l1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish YME1L1 protein expression.

    This CRISPR knockout system enables efficient generation of Yme1l1-deficient cell models for investigation of YME1L1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting Yme1l1 exon(s) critical for YME1L1 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple Yme1l1 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by YME1L1 CRISPR/Cas9 KO Plasmid (m) and YME1L1 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Yme1l1 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by YME1L1 HDR Plasmid (m) and YME1L1 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Yme1l1 homology arms to support homology-directed repair at defined Yme1l1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.